 CAMBRIDGE, Mass. and PARIS, Oct. 13, 2021 GLOBE NEWSWIRE -- Intellia Therapeutics, Inc. NASDAQ: NTLA, a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPRCas9 technology both in vivo and ex vivo, and SparingVision, a genomic medicine company developing vision saving treatments for ocular diseases, today announced a strategic collaboration to develop novel genomic medicines utilizing CRISPRCas9 technology for the treatment of ocular diseases. 